Developer docs
API playgroundTry for free, no card

Search company profiles

Alebund Pharmaceuticals

Full company profile

uuid0000ix6

Namestring
Alebund Pharmaceuticals
Legal namestring
礼邦医药(江苏)股份有限公司
Websiteurl
alebund.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Alebund Pharmaceuticals (礼邦医药集团) is a Shanghai-based clinical-stage biopharmaceutical company founded in 2018, developing innovative therapies for chronic kidney disease (CKD) and related complications. The company targets the full spectrum of CKD, addressing disease progression in early-to-mid stage patients (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD) and complications of end-stage renal disease (hyperphosphatemia, renal anemia). Its portfolio comprises eight products across six renal indications, with one commercialized product (Mircera for renal anemia, included in China's National Reimbursement Drug List) and three in clinical stage. The most advanced proprietary candidates are AP301, a novel fiber-iron-based oral phosphate binder that completed global Phase III enrollment in May 2026 with pivotal data demonstrating 66.7% serum phosphate target attainment versus 58.6% for sevelamer carbonate, and AP306 (EOS789), a first-in-class pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) licensed to R1 Therapeutics for global development outside Greater China in March 2026.

The company operates an integrated platform spanning R&D, manufacturing, and commercialization. Manufacturing is anchored by a self-built Yangzhou GMP facility with 200 metric tons/year API capacity for AP301, integrating API through finished dosage production at a single site with expansion space reserved for additional pipeline products. Distribution is executed through an in-house commercial team covering major Chinese cities and hundreds of hospitals, established via the Mircera NRDL launch. The company pursues global clinical development with multi-regional trials (U.S. and China) for late-stage assets and holds four breakthrough therapy or orphan drug designations (including NMPA Breakthrough Therapy Designation for AP306 and FDA Orphan Drug Designation for AP303).

Alebund monetizes through three streams: pharmaceutical product sales (Mircera via NRDL channels), licensing and milestone payments (notably the AP306/R1 Therapeutics deal with potential low triple-digit millions USD in milestones plus tiered low-double-digit royalties and equity participation), and future product revenue from AP301 upon China NDA submission and AP306 upon regional approvals. The company was incubated by leading nephrology industry experts and listed on the Hong Kong Stock Exchange in June 2026 (ticker 09637.HK), raising HK$1.28 billion (~$164 million). Notable investors include Quan Capital, Lilly Asia Ventures, Octagon Capital, Loyal Valley Capital, and GIC.

Short descriptiontext

Alebund Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative therapies for chronic kidney disease, with a pipeline of eight products spanning hyperphosphatemia, renal anemia, and CKD progression indications.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
renal disease therapeutics, phosphate binder drugs, biopharmaceutical pipeline, chronic kidney disease, nephrology pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Renal Disease Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from commercialized products including Mircera (methoxy polyethylene glycol-epoetin beta) for renal anemia, which has been included in China's National Reimbursement Drug List (NRDL). The company has established a commercial network covering major cities and hundreds of hospitals nationwide.

alebund.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from out-licensing arrangements including the AP306 licensing agreement with R1 Therapeutics, which includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales outside Greater China.

alebund.com
3Future Product Revenue
TypeSubscription Recurring
Description

Expected revenue from pipeline products including AP301 (hyperphosphatemia) and AP306 upon regulatory approvals. The company plans to submit AP301 NDA in China based on completed Phase III trials.

alebund.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Mircera
Description

Commercialized product for renal anemia, included in China's National Reimbursement Drug List

alebund.com
+2 more records
Core offering1 text field

Alebund Pharmaceuticals develops and commercializes innovative drug therapies for the treatment of chronic kidney disease (CKD) and related complications. The company sells Mircera for renal anemia in China through NRDL channels and is advancing a pipeline of clinical-stage candidates including AP301 (a fiber-iron-based phosphate binder for hyperphosphatemia) and AP306 (a first-in-class pan-phosphate transporter inhibitor), supported by self-built GMP manufacturing in Yangzhou and an in-house hospital-focused sales team.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AP301 Phase III: 66.7% serum phosphate target attainment rate vs 58.6% for sevelamer carbonate at Week 52
+4 more records
Product overview1 text field

Alebund Pharmaceuticals is an integrated biopharmaceutical company focused on kidney disease, with a diversified pipeline of 8 products covering the full spectrum of CKD: 1 commercialized product (Mircera® for renal anemia) and 7 pipeline candidates including 3 in clinical stage. The pipeline addresses both dialysis complications (hyperphosphatemia with AP301 and AP306) and disease progression (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD, Alport syndrome). AP301 is a next-generation fiber-iron-based phosphate binder in global Phase III for hyperphosphatemia; AP306 is a first-in-class pan-phosphate transporter inhibitor in clinical development licensed to R1 Therapeutics for global development outside Greater China. The company operates an integrated platform spanning R&D, manufacturing (Yangzhou facility with 200 metric tons/year API capacity for AP301), and commercialization.

Product and service4 records
1Mircera (methoxy polyethylene glycol-epoetin beta)
CategoryCommercialized renal anemia therapeutic
Description

A drug for renal anemia in chronic kidney disease patients, commercialized in China and included in the National Reimbursement Drug List (NRDL). Alebund distributes it through an in-house sales team covering major Chinese cities and hundreds of hospitals.

2AP301 (fiber-iron-based phosphate binder)
CategoryClinical-stage drug candidate (phosphate binder)
Description

A novel fiber-iron-based oral phosphate binder capsule for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Features high phosphate-binding capability, no need to chew before swallowing, minimal gastric fluid expansion, and no systemic absorption. Achieved 66.7% serum phosphate target attainment vs 58.6% for sevelamer carbonate at Week 52 in Phase III, with lower required daily dose (6.52 g/day vs 7.56 g/day).

3AP306 (EOS789) - Pan-sodium-dependent phosphate transporter inhibitor
CategoryClinical-stage drug candidate (phosphate transporter inhibitor)
Description

A first-in-class oral pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) for treating hyperphosphatemia in CKD patients on dialysis. Works by blocking active intestinal phosphate transport rather than binding phosphate, representing a novel mechanism of action. Phase II showed serum phosphorus reduction of -2.51 mg/dL vs -1.08 mg/dL for sevelamer carbonate at significantly lower doses (288.30 mg/day vs 4650.99 mg/day).

4AP303
CategoryClinical-stage drug candidate (ADPKD therapy)
Description

A drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) that has received FDA Orphan Drug Designation, providing accelerated regulatory pathway for the treatment of this genetic kidney disease.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Alebund granted R1 Therapeutics exclusive license to develop, manufacture, and commercialize AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales. Alebund holds substantial equity interest in R1 with anti-dilution protection. R1 launched with $77.5M Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. Companies will jointly advance global Phase 2b MRCT in U.S. and China.

2Chugai Pharmaceutical (中外制药)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Licensing agreement for AP306 (EOS789), a sodium-dependent phosphate transporter pan-inhibitor originally discovered by Chugai. Alebund completed Phase II clinical studies and has fully exercised options, now holding exclusive global development and commercialization rights for AP306.

alebund.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Strategic collaboration for innovative therapies development. Alebund has commercialized Mircera (methoxy polyethylene glycol-epoetin beta), originally from Roche, which has been included in China's NRDL.

4Peking University First Hospital
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on kidney disease research. Alebund and Peking University First Hospital jointly established a kidney disease research center. Alebund also participated in a national key R&D program on diagnostic and monitoring technologies for immune kidney diseases.

alebund.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

FibroGen developed roxadustat for anemia in CKD patients, directly competing with Alebund's Mircera franchise in the renal anemia space. Both companies pursue innovative approaches to anemia management in dialysis-dependent CKD patients and have experience commercializing renal products globally.

TypeDirect peer
Description

Travere Therapeutics is a US biopharmaceutical company developing treatments for rare kidney diseases, including sparsentan for IgA nephropathy and FSGS—indications that overlap directly with Alebund's disease-modifying CKD pipeline. Both companies target the same nephrology specialty prescriber base with novel mechanisms.

TypeBroad incumbent
Description

Vertex Pharmaceuticals has expanded into rare renal diseases through its APOL1-mediated kidney disease program (inaxaplin), positioning itself in the same nephrology specialty market Alebund targets with its CKD pipeline. While broader in therapeutic focus, Vertex is a credible competitor in nephrology innovation.

TypeEmerging player
Description

Cara Therapeutics developed difelikefalin (Korsuva) for chronic kidney disease-associated pruritus in dialysis patients—a related renal complication indication. While not a direct competitor in hyperphosphatemia or anemia, Cara addresses the same dialysis patient population with a novel mechanism.

TypeDirect peer
Description

Akebia Therapeutics develops therapeutics for kidney disease, with vadadustat for anemia due to CKD—a direct overlap with Alebund's Mircera commercial franchise. Both companies address the same dialysis/CKD patient population with anemia-focused and broader renal products.

TypeBroad incumbent
Description

Otsuka Pharmaceutical holds tolvaptan for ADPKD (Samsca/Jinarc), the only approved therapy for an indication in Alebund's early-stage pipeline (AP303 for ADPKD). Otsuka is a broad incumbent with established nephrology infrastructure that overlaps with multiple Alebund pipeline assets.

TypeDirect peer
Description

Everest Medicines is an Asia-focused biopharmaceutical company with renal franchises including Nefecon (budesonide) for IgA nephropathy. Like Alebund, Everest combines in-licensed Western assets with China/Asia commercialization infrastructure and pursues nephrology specialty indications.

TypeDirect peer
Description

Ardelyx is a US specialty biopharmaceutical company focused on renal and cardio-renal diseases, with Xphozah (tenapanor) approved for hyperphosphatemia in CKD patients on dialysis. It directly competes with Alebund's AP301 and AP306 in the same indication, patient population, and prescriber channel.

TypeDirect peer
Description

Vera Therapeutics is a clinical-stage biotech developing atacicept for IgA nephropathy, a key indication in Alebund's disease-modifying CKD pipeline. Both companies target nephrology specialty physicians with novel biologics addressing immune-mediated kidney diseases.

TypeBroad incumbent
Description

CSL Vifor (formerly Vifor Pharma) is the global market leader in iron deficiency and nephrology pharmaceuticals, with established phosphate binder franchises (e.g., Velphoro). It represents a broad incumbent competitor across Alebund's dialysis-complication and renal anemia therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alebund Pharmaceuticals

Renal Disease Pharmaceuticalsalebund.com

Alebund Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative therapies for chronic kidney disease, with a pipeline of eight products spanning hyperphosphatemia, renal anemia, and CKD progression indications.

What Alebund Pharmaceuticals does

Alebund Pharmaceuticals (礼邦医药集团) is a Shanghai-based clinical-stage biopharmaceutical company founded in 2018, developing innovative therapies for chronic kidney disease (CKD) and related complications. The company targets the full spectrum of CKD, addressing disease progression in early-to-mid stage patients (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD) and complications of end-stage renal disease (hyperphosphatemia, renal anemia). Its portfolio comprises eight products across six renal indications, with one commercialized product (Mircera for renal anemia, included in China's National Reimbursement Drug List) and three in clinical stage. The most advanced proprietary candidates are AP301, a novel fiber-iron-based oral phosphate binder that completed global Phase III enrollment in May 2026 with pivotal data demonstrating 66.7% serum phosphate target attainment versus 58.6% for sevelamer carbonate, and AP306 (EOS789), a first-in-class pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) licensed to R1 Therapeutics for global development outside Greater China in March 2026.

The company operates an integrated platform spanning R&D, manufacturing, and commercialization. Manufacturing is anchored by a self-built Yangzhou GMP facility with 200 metric tons/year API capacity for AP301, integrating API through finished dosage production at a single site with expansion space reserved for additional pipeline products. Distribution is executed through an in-house commercial team covering major Chinese cities and hundreds of hospitals, established via the Mircera NRDL launch. The company pursues global clinical development with multi-regional trials (U.S. and China) for late-stage assets and holds four breakthrough therapy or orphan drug designations (including NMPA Breakthrough Therapy Designation for AP306 and FDA Orphan Drug Designation for AP303).

Alebund monetizes through three streams: pharmaceutical product sales (Mircera via NRDL channels), licensing and milestone payments (notably the AP306/R1 Therapeutics deal with potential low triple-digit millions USD in milestones plus tiered low-double-digit royalties and equity participation), and future product revenue from AP301 upon China NDA submission and AP306 upon regional approvals. The company was incubated by leading nephrology industry experts and listed on the Hong Kong Stock Exchange in June 2026 (ticker 09637.HK), raising HK$1.28 billion (~$164 million). Notable investors include Quan Capital, Lilly Asia Ventures, Octagon Capital, Loyal Valley Capital, and GIC.

Alebund Pharmaceuticals firmographics

Firmographics
Name
Alebund Pharmaceuticals
Legal name
礼邦医药(江苏)股份有限公司
Website
https://alebund.com
Company type
Public
Founded year
2018
Operating status
Ipo
Headcount range
11–50 employees
Short description
Alebund Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative therapies for chronic kidney disease, with a pipeline of eight products spanning hyperphosphatemia, renal anemia, and CKD progression indications.
Ownership category
akta.pro rank

Alebund Pharmaceuticals industry classification

Industry
Product category
Renal Disease Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Renal disease therapeutics
  • Phosphate binder drugs
  • Biopharmaceutical pipeline
  • Chronic kidney disease
  • Nephrology pharmaceuticals

Where Alebund Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Alebund Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue from commercialized products including Mircera (methoxy polyethylene glycol-epoetin beta) for renal anemia, which has been included in China's National Reimbursement Drug List (NRDL). The company has established a commercial network covering major cities and hundreds of hospitals nationwide.
  2. Licensing and Milestone Payments: Revenue from out-licensing arrangements including the AP306 licensing agreement with R1 Therapeutics, which includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales outside Greater China.
  3. Future Product Revenue: Expected revenue from pipeline products including AP301 (hyperphosphatemia) and AP306 upon regulatory approvals. The company plans to submit AP301 NDA in China based on completed Phase III trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Alebund Pharmaceuticals product offering

Product offering

Core offering

Alebund Pharmaceuticals develops and commercializes innovative drug therapies for the treatment of chronic kidney disease (CKD) and related complications. The company sells Mircera for renal anemia in China through NRDL channels and is advancing a pipeline of clinical-stage candidates including AP301 (a fiber-iron-based phosphate binder for hyperphosphatemia) and AP306 (a first-in-class pan-phosphate transporter inhibitor), supported by self-built GMP manufacturing in Yangzhou and an in-house hospital-focused sales team.

Product overview

Alebund Pharmaceuticals is an integrated biopharmaceutical company focused on kidney disease, with a diversified pipeline of 8 products covering the full spectrum of CKD: 1 commercialized product (Mircera® for renal anemia) and 7 pipeline candidates including 3 in clinical stage. The pipeline addresses both dialysis complications (hyperphosphatemia with AP301 and AP306) and disease progression (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD, Alport syndrome). AP301 is a next-generation fiber-iron-based phosphate binder in global Phase III for hyperphosphatemia; AP306 is a first-in-class pan-phosphate transporter inhibitor in clinical development licensed to R1 Therapeutics for global development outside Greater China. The company operates an integrated platform spanning R&D, manufacturing (Yangzhou facility with 200 metric tons/year API capacity for AP301), and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

  • Mircera: Commercialized product for renal anemia, included in China's National Reimbursement Drug List
  • AP301
  • AP306

Products and services

  • Mircera (methoxy polyethylene glycol-epoetin beta) A drug for renal anemia in chronic kidney disease patients, commercialized in China and included in the National Reimbursement Drug List (NRDL). Alebund distributes it through an in-house sales team covering major Chinese cities and hundreds of hospitals.
  • AP301 (fiber-iron-based phosphate binder) A novel fiber-iron-based oral phosphate binder capsule for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Features high phosphate-binding capability, no need to chew before swallowing, minimal gastric fluid expansion, and no systemic absorption. Achieved 66.7% serum phosphate target attainment vs 58.6% for sevelamer carbonate at Week 52 in Phase III, with lower required daily dose (6.52 g/day vs 7.56 g/day).
  • AP306 (EOS789) - Pan-sodium-dependent phosphate transporter inhibitor A first-in-class oral pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) for treating hyperphosphatemia in CKD patients on dialysis. Works by blocking active intestinal phosphate transport rather than binding phosphate, representing a novel mechanism of action. Phase II showed serum phosphorus reduction of -2.51 mg/dL vs -1.08 mg/dL for sevelamer carbonate at significantly lower doses (288.30 mg/day vs 4650.99 mg/day).
  • AP303 A drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) that has received FDA Orphan Drug Designation, providing accelerated regulatory pathway for the treatment of this genetic kidney disease.

Quantifiable outcome

  • AP301 Phase III: 66.7% serum phosphate target attainment rate vs 58.6% for sevelamer carbonate at Week 52
  • +4 more outcomes

Companies that use Alebund Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Alebund Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alebund Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and strategic.

  • R1 TherapeuticscoreStrategic or Co-development Partner · 17 March 2026Alebund granted R1 Therapeutics exclusive license to develop, manufacture, and commercialize AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales. Alebund holds substantial equity interest in R1 with anti-dilution protection. R1 launched with $77.5M Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. Companies will jointly advance global Phase 2b MRCT in U.S. and China.
  • Chugai Pharmaceutical (中外制药)coreTechnology or Integration · 1 January 2021Licensing agreement for AP306 (EOS789), a sodium-dependent phosphate transporter pan-inhibitor originally discovered by Chugai. Alebund completed Phase II clinical studies and has fully exercised options, now holding exclusive global development and commercialization rights for AP306.
  • RochestrategicStrategic or Co-development PartnerStrategic collaboration for innovative therapies development. Alebund has commercialized Mircera (methoxy polyethylene glycol-epoetin beta), originally from Roche, which has been included in China's NRDL.
  • Peking University First HospitalstrategicStrategic or Co-development PartnerCollaboration on kidney disease research. Alebund and Peking University First Hospital jointly established a kidney disease research center. Alebund also participated in a national key R&D program on diagnostic and monitoring technologies for immune kidney diseases.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Alebund Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • FibroGen: FibroGen developed roxadustat for anemia in CKD patients, directly competing with Alebund's Mircera franchise in the renal anemia space. Both companies pursue innovative approaches to anemia management in dialysis-dependent CKD patients and have experience commercializing renal products globally.
  • Travere Therapeutics: Travere Therapeutics is a US biopharmaceutical company developing treatments for rare kidney diseases, including sparsentan for IgA nephropathy and FSGS—indications that overlap directly with Alebund's disease-modifying CKD pipeline. Both companies target the same nephrology specialty prescriber base with novel mechanisms.
  • Akebia Therapeutics: Akebia Therapeutics develops therapeutics for kidney disease, with vadadustat for anemia due to CKD—a direct overlap with Alebund's Mircera commercial franchise. Both companies address the same dialysis/CKD patient population with anemia-focused and broader renal products.
  • Everest Medicines: Everest Medicines is an Asia-focused biopharmaceutical company with renal franchises including Nefecon (budesonide) for IgA nephropathy. Like Alebund, Everest combines in-licensed Western assets with China/Asia commercialization infrastructure and pursues nephrology specialty indications.
  • Ardelyx: Ardelyx is a US specialty biopharmaceutical company focused on renal and cardio-renal diseases, with Xphozah (tenapanor) approved for hyperphosphatemia in CKD patients on dialysis. It directly competes with Alebund's AP301 and AP306 in the same indication, patient population, and prescriber channel.
  • Vera Therapeutics: Vera Therapeutics is a clinical-stage biotech developing atacicept for IgA nephropathy, a key indication in Alebund's disease-modifying CKD pipeline. Both companies target nephrology specialty physicians with novel biologics addressing immune-mediated kidney diseases.

Broad incumbents

  • Vertex Pharmaceuticals: Vertex Pharmaceuticals has expanded into rare renal diseases through its APOL1-mediated kidney disease program (inaxaplin), positioning itself in the same nephrology specialty market Alebund targets with its CKD pipeline. While broader in therapeutic focus, Vertex is a credible competitor in nephrology innovation.
  • Otsuka Pharmaceutical: Otsuka Pharmaceutical holds tolvaptan for ADPKD (Samsca/Jinarc), the only approved therapy for an indication in Alebund's early-stage pipeline (AP303 for ADPKD). Otsuka is a broad incumbent with established nephrology infrastructure that overlaps with multiple Alebund pipeline assets.
  • CSL Vifor: CSL Vifor (formerly Vifor Pharma) is the global market leader in iron deficiency and nephrology pharmaceuticals, with established phosphate binder franchises (e.g., Velphoro). It represents a broad incumbent competitor across Alebund's dialysis-complication and renal anemia therapeutic areas.

Emerging players

  • Cara Therapeutics: Cara Therapeutics developed difelikefalin (Korsuva) for chronic kidney disease-associated pruritus in dialysis patients—a related renal complication indication. While not a direct competitor in hyperphosphatemia or anemia, Cara addresses the same dialysis patient population with a novel mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Alebund Pharmaceuticals social profiles

Digital presence

Alebund Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alebund Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles12 records

Alebund Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alebund Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alebund Pharmaceuticals

What does Alebund Pharmaceuticals do?

Alebund Pharmaceuticals develops and commercializes innovative drug therapies for the treatment of chronic kidney disease (CKD) and related complications. The company sells Mircera for renal anemia in China through NRDL channels and is advancing a pipeline of clinical-stage candidates including AP301 (a fiber-iron-based phosphate binder for hyperphosphatemia) and AP306 (a first-in-class pan-phosphate transporter inhibitor), supported by self-built GMP manufacturing in Yangzhou and an in-house hospital-focused sales team.

Is Alebund Pharmaceuticals a public or private company?

Alebund Pharmaceuticals is a public company. It is classified as public and is currently ipo.

When was Alebund Pharmaceuticals founded?

Alebund Pharmaceuticals was founded in 2018. It employs 11 to 50 people.

Where is Alebund Pharmaceuticals based?

Alebund Pharmaceuticals is headquartered in Shanghai, China, in the Asia region.

How does Alebund Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Milestone Payments and future Product Revenue.

Who are Alebund Pharmaceuticals's main competitors?

Direct peers on record are FibroGen, Travere Therapeutics, Akebia Therapeutics, Everest Medicines, Ardelyx and Vera Therapeutics. Broad incumbents are Vertex Pharmaceuticals, Otsuka Pharmaceutical and CSL Vifor. Cara Therapeutics is listed as an emerging player.

Does Alebund Pharmaceuticals have an API?

No public API is recorded for Alebund Pharmaceuticals.

What industry is Alebund Pharmaceuticals in?

Alebund Pharmaceuticals's product category is Renal Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAM, Nephrology & Urology Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACAlebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA NephropathyAlebund Pharmaceuticals received FDA clearance for its IND application for AP308, a first-in-class engineered recombinant IgA protease for IgA nephropathy. The company plans to initiate the clinical trial in the near term. Preclinical data showed AP308 reduced IgA and IgA immune complexes by about 80% in a mouse model.Laotian TimesAlebund Pharmaceuticals Announces 2026 Interim ResultsAlebund Pharmaceuticals reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB104.2 million, up 761.2% from RMB12.1 million, with a net loss of RMB162.6 million, down 22.5% year-on-year. Cash and equivalents totaled RMB1,392.8 million. AP301's NMPA application was accepted for review on August 7, 2026, and AP306's Phase IIb trial is expected to finish in Q2 2027.Stock TitanAlebund Pharmaceuticals H1 Results: Revenue Up 761.2%Alebund Pharmaceuticals reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB104.2 million, up 761.2% from RMB12.1 million, driven by RMB79.3 million in licensing revenue from R1 Therapeutics and RMB24.8 million from Mircera. Net loss narrowed 22.5% to RMB162.6 million, with adjusted net loss of RMB130.1 million.PR Newswire APACAlebund Pharmaceuticals Announces 2026 Interim ResultsAlebund Pharmaceuticals reported first-half 2026 revenue of RMB104.2 million, up 761.2% year-on-year, with a net loss of RMB162.6 million, down 22.5%. The company completed patient enrollment in its AP301 Phase III trial and initiated the AP306 Phase IIb trial, with licensing revenue of RMB79.3 million from R1.AijournAlebund’s AP301 NDA Accepted for Review by China’s NMPAAlebund Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application for AP301, a novel oral iron-based phosphate binder for treating hyperphosphatemia in dialysis patients. The acceptance is based on data from the pivotal RESPOND-1 Phase III trial, which demonstrated the drug's efficacy and safety profile compared to sevelamer carbonate over a 52-week period. This regulatory milestone marks a significant step toward commercialization and potential market entry for Alebund's renal-focused therapy.Laotian TimesAlebund’s AP301 NDA Accepted for Review by China’s NMPAAlebund Pharmaceuticals announced that its New Drug Application (NDA) for AP301 capsules, aimed at treating hyperphosphatemia in patients with chronic kidney disease receiving maintenance dialysis, has been accepted for review by China's National Medical Products Administration (NMPA). The NDA is primarily supported by the results of the pivotal Phase III clinical trial, where AP301 showed significant efficacy in lowering serum phosphate levels compared to a comparator drug, sevelamer carbonate. This acceptance marks a critical step in Alebund's strategy to bring innovative treatment options to patients globally.PR Newswire APACAlebund's AP301 NDA Accepted for Review by China's NMPAAlebund Pharmaceuticals' NDA for AP301 capsules, a novel oral phosphate binder, has been accepted for review by China's NMPA. The NDA is supported by Phase III clinical trial results showing the drug's efficacy and safety in reducing serum phosphate levels in patients with CKD on dialysis.PR NewswireAlebund's AP301 NDA Accepted for Review by China's NMPAAlebund Pharmaceuticals announced that China's NMPA has formally accepted for review the NDA for AP301 capsules, a novel oral iron-based phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease receiving maintenance dialysis. The NDA is supported by results from RESPOND-1, a pivotal Phase III clinical trial completed in China with 474 patients randomized 3:1, which met both pre-specified primary efficacy endpoints and demonstrated non-inferiority and statistical superiority over sevelamer carbonate in reducing serum phosphate levels over 52 weeks. The company stated this acceptance marks a key step in advancing its proprietary products toward commercialization, with plans to accelerate launch preparations using its manufacturing base in Yangzhou.MorningstarAlebund's AP301 NDA Accepted for Review by China's NMPAAlebund's AP301 NDA for a phosphate binder in dialysis patients was accepted for review by China's NMPA. The pivotal RESPOND-1 trial showed AP301 was non-inferior to sevelamer carbonate in reducing serum phosphate over 52 weeks. The company plans to accelerate preparations for launch.PR NewswireHyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsightThe hyperphosphatemia market is projected to grow through 2036, driven by rising chronic kidney disease and dialysis populations. Prevalence reaches 2.3% in CKD stages III–IV, and emerging therapies like TS-172 and AP-301 are expected to reshape treatment. The US led the 7MM in 2025.